Controlled-release morphine tablets in patients with chronic cancer pain: A narrative review of controlled clinical trials

Cancer

Volumn 82, Issue 12, 1998, Pages 2299-2306

  Warfield, Carol A ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Controlled clinical trials; Controlled release; Immediate release; Morphine; Pain

Indexed keywords

MORPHINE; MORPHINE SULFATE;

CANCER PAIN; CHRONIC PAIN; CLINICAL TRIAL; CONSTIPATION; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HUMAN; NAUSEA; ORAL DRUG ADMINISTRATION; PAIN ASSESSMENT; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEDATION; TABLET FORMULATION; VERTIGO;

ADMINISTRATION, ORAL; ANALGESICS, OPIOID; CONTROLLED CLINICAL TRIALS; HUMANS; MORPHINE; NEOPLASMS; PAIN; TREATMENT OUTCOME;

EID: 0032526080     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980615)82:12<2299::AID-CNCR1>3.0.CO;2-O     Document Type: Review

References (37)

1. Leslie ST. Continuous controlled release preparations. Br J Clin Pract 1981;35 (Suppl 10):5-8.
2. Ferrell B, Wisdom C, Wenzl C, Brown J. Effect of controlled-release morphine on quality of life for cancer pain. Oncol Nurs Forum 1989;16:521-6.
3. National Disease and Therapeutic Index™ on Dataview Database [on CD ROM]. Plymouth Meeting, PA: IMS America, January 1994-December 1996.
4. Levy MH. Oral controlled release morphine: guidelines for clinical use. In: Benedetti C, Chapman CR, Giron G, editors. Advances in pain research and therapy. Volume 14. New York: Raven Press, 1990:285-95.
5. Warfield CA. Guidelines for routine use of controlled-release oral morphine sulfate tablets. Semin Oncol 1993;20(2 Suppl 1):36-47.
6. Bonica JJ. Cancer pain. In: Bonica JJ, editor. The management of pain. 2nd edition. Volume 1. Philadelphia: Lea & Febiger; 1990:432-3.
7. Woodforde JM, Merskey H. Some relationships between subjective measures of pain. J Psychosom Res 1972;16:173-8.
8. Downie WW, Leatham PA, Rhind VM, Wright V, Branco JA, Anderson JA. Studies with pain rating scales. Ann Rheum Dis 1978;37:378-81.
9. Wallenstein SL. Scaling clinical pain and pain relief. In: Bromm B, editor. Pain measurement in man: neurophysiological correlates of pain. Amsterdam: Elsevier Science Publishers, 1984:389-96.
10. Kremer E, Atkinson JH, Ignelzi RJ. Measurement of pain: patient preference does not confound pain measurement. Pain 1981;10:241-8.
11. Ahles TA, Ruckdeschel JC, Blanchard EB. Cancer-related pain. II. Assessment with visual analogue scales. J Psychosom Res 1984;28:121-4.
12. Littman GS, Walker BR, Schneider BE. Reassessment of verbal and visual analog ratings in analgesic studies. Clin Pharmacol Ther 1985;38:16-23.
13. Jensen MP, Karoly P, Braver S. The measurement of clinical pain intensity: a comparison of six methods. Pain 1986;27: 117-26.
14. Henriksen H, Knudsen J. MST Continuos tablets in pain of advanced cancer: a controlled study. In: Wilkes E, Levy J, editors. Advances in morphine therapy. The 1983 International Symposium on Pain Control. International Congress and Symposium Series 64. London: Royal Society of Medicine, 1984:123-6.
15. Welsh J, Stuart JHB, Haveshaw T, Billiaert P, Caiman KC. A double blind cross-over study of two oral formulations of morphine. In: Harrap KR, Davis W, Calvert AH, editors. Cancer chemotherapy and selective drug development. Boston: Martinus Nijhoff, 1984:153-8.
16. Hanks GW, Twycross RG, Bliss JM. Controlled release morphine tablets: a double-blind trial in patients with advanced cancer. Anaesthesia 1987;42:840-4.
17. Cundiff D, McCarthy K, Savarese JJ, Kaiko R, Thomas G, Grandy R, et al. Evaluation of a cancer pain model for the testing of long-acting analgesics: the effect of MS Contin in a double-blind, randomized crossover design. Cancer 1989; 63:2355-9.
18. Goughnour BR, Arkinstall WW, Stewart JH. Analgesic response to single and multiple doses of controlled-release morphine tablets and morphine oral solution in cancer patients. Cancer 1989;63:2294-7.
19. Portenoy RK, Maldonado M, Fitzmartin R, Kaiko RF, Kanner R. Oral controlled-release morphine sulfate: analgesic efficacy and side effects of a 100-mg tablet in cancer pain patients. Cancer 1989;63:2284-8.
20. Thirlwell MP, Sloan PA, Maroun JA, Boos GJ, Besner J-G, Stewart JH, et al. Pharmacokinetics and clinical efficacy of oral morphine solution and controlled-release morphine tablets in cancer patients. Cancer 1989;63:2275-83.
21. Boureau F, Saudubray F, d'Arnoux C, Vedrenne J, Estève M, Roquefeuil B, et al. A comparative study of controlled-release morphine (CRM) suspension and CRM tablets in chronic cancer pain. J Pain Symptom Manage 1992;7:393-9.
22. Deschamps M, Band PR, Hislop TG, Rusthoven J, Iscoe N, Warr D. The evaluation of analgesic effects in cancer patients as exemplified by a double-blind, crossover study of immediate-release versus controlled-release morphine. J Pain Symptom Manage 1992;7:384-92.
23. Mignault GG, Latreille J, Viguié F, Richer P, Lemire F, Harsanyi Z, et al. Control of cancer-related pain with MS Contin®: a comparison between 12-hourly and 8-hourly administration. J Pain Symptom Manage 1995;10:416-22.
24. Walsh TD. A controlled study of MST Continuos tablets for chronic pain in advanced cancer. In: Wilkes E, Levy J, editors. Advances in morphine therapy. The 1983 International Symposium on Pain Control. International Congress and Symposium Series 64. London: Royal Society of Medicine, 1984:99-102.
25. Walsh TD. Clinical evaluation of slow-release morphine tablets. In: Fields HL, Dubner R, Cervero F, editors. Advances in pain research and therapy. Volume 9. New York: Raven Press, 1985:727-31.
26. Walsh T. Modern use of opiates in advanced cancer: a reappraisal. In: Band PR, Stewart JH, Towson RT, editors. Advances in the management of chronic pain. The International Symposium on Pain Control. Toronto: Purdue Frederick, Inc, 1986:47-9.
27. Hanks GW. Controlled release morphine tablets in chronic cancer pain: a review of controlled clinical trials. In: Benedetti C, Chapman CR, Giron G, editors. Advances in pain research and therapy. Volume 14. New York: Raven Press, 1990;14:269-74.
28. Melzack R, Ofiesh JG, Mount BM. The Brompton mixture: effects on pain in cancer patients. Can Med Assoc J 1976;115: 125-9.
29. Melzack R, Mount BM, Gordon JM. The Brompton mixture versus morphine solution given orally: effects on pain. Can Med Assoc J 1979;120:435-9.
30. Savarese JJ, Goldenheim PD, Thomas GB, Kaiko RF. Steadystate pharmacokinetics of controlled release oral morphine sulphate in healthy subjects. Clin Pharmacokinet 1986;11: 505-10.
31. Marshall HUW, Porteous C, McMillan I, MacPherson SG, Nimmo WS. Relief of pain by infusion of morphine after operation: does tolerance develop? BMJ 1985;291:19-21.
32. Paalzow LK. Pharmacokinetic/pharmacodynamic aspects of controlled release products. Presented at the Swedish Academy of Pharmaceutical Sciences FIP-Satellite Symposium on Optimizing Therapy Using Controlled Release Products, Stockholm, Sweden, August 25-26, 1995.
33. Gourlay GK, Plummer JL, Cherry DA, Onley MM. A comparison of Kapanol (a new sustained-release morphine formulation), MST Continues, and morphine solution in cancer patients: pharmacokinetic aspects of morphine and morphine metabolites. In: Gebhart GF, Hammond DL, Jensen TS, editors. Proceedings of the 7th World Congress on Pain. Seattle: IASP Press, 1994:631-43.
34. Gourlay GK, Cherry DA, Onley MM, Tordoff SG, Conn DA, Hood GM, et al. Phamiacokinetics and pharmacodynamics of twenty-four-hourly Kapanol compared to twelve-hourly MS Contin in the treatment of severe cancer pain. Pain 1997;69:295-302.
35. Maccarrone C, West RJ, Broomhead AF, Hodsman GP. Single dose pharmacokinetics of Kapanol™, a new oral sustained-release morphine formulation. Drug Invest 1994;7:262-74.
36. Hunt TL, Kaiko RF. Comparison of the pharmacokinetic profiles of two oral controlled-release morphine formulations in healthy young adults. Clin Ther 1991;13:482-8.
37. Schobelock MJ, Shepard KV, Mosdell KW, Lee J, Hulse JD. Multiple-dose pharmacokinetic evaluation of two formulations of sustained release morphine sulfate tablets. Curr Ther Res 1995;56:1009-21.